Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PTGIR | P43119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376813 | 1.00 | P2RX7 (0.37) | P2RX7PTGER4EPHX2SIGMAR1PTGER2 | |
| SCHEMBL1376751 | 0.91 | P2RX7 (0.38) | P2RX7PTGER4EPHX2SIGMAR1THRB | |
| SCHEMBL4381028 | 0.91 | P2RX7 (0.38) | P2RX7PTGER4EPHX2SIGMAR1THRB | |
| SCHEMBL4376260 | 0.90 | CHRM2 (0.35) | P2RX7PTGER4 | |
| SCHEMBL4376256 | 0.90 | CHRM2 (0.35) | P2RX7PTGER4 | |
| SCHEMBL14277405 | 0.88 | CHRM2 (0.34) | PTGER4 | |
| SCHEMBL4377884 | 0.85 | PTGER3 (0.44) | PTGER4PTGER2 | |
| SCHEMBL4377882 | 0.85 | PTGER3 (0.44) | PTGER4PTGER2 | |
| SCHEMBL4377888 | 0.85 | PTGER3 (0.44) | PTGER4PTGER2 | |
| SCHEMBL4379670 | 0.82 | HCRTR1 (0.35) | P2RX7PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817033-B1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN INC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7326716-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7179820-B2 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050171062-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | ALLERGAN, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171062-A1 | Treatment of inflammatory bowel disease | SLC10A2, GUCY1B1, PTGER1 | P2RX7 1124/4885PTGER4 18/4885EPHX2 293/4885 |
| US-20040248854-A1 | Piperidinyl prostaglandin E analogs | PTGIR, PTGER1, PTGS1 | P2RX7 184/4885PTGER4 14/4885EPHX2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.